Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""fms-Like Tyrosine Kinase 3"" wg kryterium: Temat


Tytuł:
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Autorzy:
Chen N; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Pan J; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Zhou Y; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Mao L; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Lou Y; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Qian J; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Xu G; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Wei J; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Zhou; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Shou L; Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang, PR China.
Huang L; Jinhua People's Hospital, Jinhua, Zhejiang, PR China.
Yan M; Department of Hematology, the First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, PR China.
Zeng H; Department of Hematology, the First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, PR China.
Fan C; Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, PR China.
Wu G; Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People's Hospital, Dongyang, Zhejiang, PR China.
Feng W; Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang, PR China.
Tong H; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Jin J; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, PR China.
Wang H; Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, PR China.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2024 Mar; Vol. 204 (3), pp. 861-870. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*
Leukemia, Myeloid, Acute*
Aniline Compounds*
Pyrazines*
Sulfonamides*
Bridged Bicyclo Compounds, Heterocyclic*
Adult ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Autorzy:
Lee JK; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
Chatterjee A; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Scarpa M; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Bailey CM; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Niyongere S; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Singh P; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
Mustafa Ali MK; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Kapoor S; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
Wang Y; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
Silvestri G; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; Veterans Affairs Medical Center, Baltimore, Maryland.
Pokaż więcej
Źródło:
Cancer research communications [Cancer Res Commun] 2024 Feb 16; Vol. 4 (2), pp. 431-445.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Aniline Compounds*
Pyrazines*
Humans ; Glycogen Synthase Kinase 3 beta/genetics ; Protein Serine-Threonine Kinases/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Serine/metabolism
Czasopismo naukowe
Tytuł:
Design and synthesis 1H-Pyrrolo[2,3-b]pyridine derivatives as FLT3 inhibitors for the treatment of Acute myeloid Leukemia.
Autorzy:
Wei TH; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Zhou Y; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Yang J; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Zhang MY; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Wang JJ; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Tong ZJ; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Wu JZ; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Wang YB; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Sha JK; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Chen M; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Ding N; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Yu YC; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Dai WC; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China; Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China.
Leng XJ; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Xue X; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
Sun SL; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China. Electronic address: .
Wang XL; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China. Electronic address: .
Li NG; National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China. Electronic address: .
Shi ZH; Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2024 Feb 15; Vol. 100, pp. 117631. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/metabolism
Humans ; Apoptosis ; Cell Line, Tumor ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Pyridines/pharmacology
Czasopismo naukowe
Tytuł:
Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
Autorzy:
Liu W; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Bai Y; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Zhou L; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou, 511400, China.
Jin J; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Zhang M; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Wang Y; Livzon Research Institute, Livzon Pharmaceutical Group Inc., #38 Chuangye North Road, Jinwan District, Zhuhai, 519000, China.
Lin R; Livzon Research Institute, Livzon Pharmaceutical Group Inc., #38 Chuangye North Road, Jinwan District, Zhuhai, 519000, China.
Huang W; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Ren X; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Ma N; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou, 511400, China.
Zhou F; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou, 511400, China.
Wang Z; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China.
Ding K; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou, 511400, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2024 Jan 15; Vol. 264, pp. 115974. Date of Electronic Publication: 2023 Nov 19.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/pathology
Humans ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Mutation ; Cell Proliferation ; Apoptosis
Czasopismo naukowe
Tytuł:
Bayesian Optimization in the Latent Space of a Variational Autoencoder for the Generation of Selective FLT3 Inhibitors.
Autorzy:
Chandra R; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
Horne RI; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
Vendruscolo M; Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.
Pokaż więcej
Źródło:
Journal of chemical theory and computation [J Chem Theory Comput] 2024 Jan 09; Vol. 20 (1), pp. 469-476. Date of Electronic Publication: 2023 Dec 19.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*
Drug Design*
Bayes Theorem
Czasopismo naukowe
Tytuł:
The Potential Transcriptomic and Metabolomic Mechanisms of ATO and ATRA in Treatment of FLT3-ITD Acute Myeloid Leukemia.
Autorzy:
Peng CJ; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Fan Z; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Luo JS; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Wang LN; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Li Y; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Liang C; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zhang XL; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Luo XQ; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Huang LB; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Tang YL; Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Pokaż więcej
Źródło:
Technology in cancer research & treatment [Technol Cancer Res Treat] 2024 Jan-Dec; Vol. 23, pp. 15330338231223080.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Humans ; Arsenic Trioxide/pharmacology ; Transcriptome ; Tretinoin/pharmacology ; Tretinoin/therapeutic use ; Mutation ; Gene Expression Profiling ; Fatty Acids/therapeutic use
Czasopismo naukowe
Tytuł:
Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.
Autorzy:
Ko B; School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, South Korea.
Jang Y; School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, South Korea.
Kim MH; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Gyeongsangnam-do, 52828, South Korea.
Lam TT; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Gyeongsangnam-do, 52828, South Korea.
Seo HK; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Gyeongsangnam-do, 52828, South Korea.
Jeong P; School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, South Korea.
Choi M; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, South Korea.
Kang KW; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, South Korea.
Lee SD; R&D Center, PeLeMed, Co. Ltd, Seoul, 06100, South Korea.
Park JH; R&D Center, PeLeMed, Co. Ltd, Seoul, 06100, South Korea.
Kim M; R&D Center, PeLeMed, Co. Ltd, Seoul, 06100, South Korea.
Han SY; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Gyeongsangnam-do, 52828, South Korea. Electronic address: .
Kim YC; School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, South Korea; Center for AI-Applied High Efficiency Drug Discovery (AHEDD), Gwangju Institute of Science and Technology (GIST), Gwangju, 61005, South Korea; R&D Center, PeLeMed, Co. Ltd, Seoul, 06100, South Korea. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2023 Dec 15; Vol. 262, pp. 115860. Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/metabolism
Humans ; Indazoles/pharmacology ; Molecular Docking Simulation ; Cell Line, Tumor ; Mutation ; Protein Kinase Inhibitors/chemistry
Czasopismo naukowe
Tytuł:
Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.
Autorzy:
Lian X; ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Gao Y; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Li X; ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Wang P; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Tong L; ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, Zhejiang 310018, China.
Li J; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong 528400, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Electronic address: .
Zhou Y; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong 528400, China. Electronic address: .
Liu T; ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2023 Nov 15; Vol. 96, pp. 129519. Date of Electronic Publication: 2023 Oct 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Protein Kinase Inhibitors/pharmacology ; Cell Line, Tumor ; Mutation ; Apoptosis
Czasopismo naukowe
Tytuł:
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Autorzy:
Peschke JC; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Partner Site, Dresden, Germany.
Bergmann R; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.
Mehnert M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
Gonzalez Soto KE; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Loureiro LR; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Mitwasi N; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Kegler A; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Altmann H; National Center for Tumor Diseases Dresden (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Partner Site, Dresden, Germany.; Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wobus M; Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Máthé D; Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.; Hungarian Centre of Excellence for Molecular Medicine, In Vivo Imaging Advanced Core Facility, Szeged, Hungary.
Szigeti K; Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.
Feldmann A; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Partner Site, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bornhäuser M; National Center for Tumor Diseases Dresden (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Partner Site, Dresden, Germany.; Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; School of Cancer and Pharmaceutical Science, King's College, London, UK.
Bachmann M; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; National Center for Tumor Diseases Dresden (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Partner Site, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Fasslrinner F; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.; Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Arndt C; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2023 Sep; Vol. 202 (6), pp. 1137-1150. Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
fms-Like Tyrosine Kinase 3*/metabolism
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Animals ; Mice ; Immunotherapy, Adoptive ; T-Lymphocytes ; Antigens, Neoplasm
Czasopismo naukowe
Tytuł:
PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia.
Autorzy:
Choi YJ; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Park J; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Choi H; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Oh SJ; R&D Center, PeLeMed, Co. Ltd., Seoul 06100, Republic of Korea.
Park JH; R&D Center, PeLeMed, Co. Ltd., Seoul 06100, Republic of Korea.
Park M; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Kim JW; Jeju Research Institute of Pharmaceutical Sciences, College of Pharmacy, Jeju National University, Jeju 63243, Republic of Korea.
Kim YG; College of Pharmacy, Dankook University, Cheonan 31116, Republic of Korea.
Kim YC; R&D Center, PeLeMed, Co. Ltd., Seoul 06100, Republic of Korea; School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
Kim MJ; R&D Center, PeLeMed, Co. Ltd., Seoul 06100, Republic of Korea. Electronic address: .
Kang KW; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Sep; Vol. 165, pp. 115066. Date of Electronic Publication: 2023 Jun 29.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/metabolism
Adult ; Humans ; Protein Kinase Inhibitors/adverse effects ; Mutation ; Proto-Oncogene Proteins c-ret/genetics
Czasopismo naukowe
Tytuł:
Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor.
Autorzy:
Zhi Y; School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, 450046, PR China.
Li H; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Yang P; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Jin Q; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Yao C; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Li B; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Ling J; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Guo H; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Li T; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Jin J; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China.
Wang Y; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China. Electronic address: zwy_.
Chen Y; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China. Electronic address: .
Lu T; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China. Electronic address: .
Lu S; School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China. Electronic address: lu_.
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2023 Aug 05; Vol. 256, pp. 115448. Date of Electronic Publication: 2023 May 03.
Typ publikacji:
Journal Article
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/pathology
Dogs ; Animals ; Rats ; Cell Line, Tumor ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/pharmacology
Czasopismo naukowe
Tytuł:
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Autorzy:
Perl AE; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: .
Larson RA; Division of the Biological Sciences, University of Chicago, Chicago, Illinois.
Podoltsev NA; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Strickland S; Department of Internal Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Wang ES; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Atallah E; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Schiller GJ; Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Martinelli G; IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori 'Dino Amadori' IRST S.r.l, Meldola, Italy.
Neubauer A; Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany.
Sierra J; Hospital de la Santa Creu i Sant Pau and Josep Carreras Leukemia Research Institute, Barcelona, Spain.
Montesinos P; Department of Hematology, University Hospital La Fe, Valencia, Spain.
Recher C; Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France.
Yoon SS; Department of Hemato Oncology, Seoul National University Hospital, Seoul, Republic of Korea.
Maeda Y; Department of Hematology and Oncology, Okayama University Hospital, Okoyama, Japan.
Hosono N; Department of Internal Medicine, University of Fukui, Fukui, Japan.
Onozawa M; Department of Hematology, Hokkaido University, Sapporo, Japan.
Kato T; Department of Hematology, University of Tsukuba, Tsukuba, Japan.
Kim HJ; Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hasabou N; Astellas Pharma US, Inc., Northbrook, Illinois.
Nuthethi R; Astellas Pharma US, Inc., Northbrook, Illinois.
Tiu R; Astellas Pharma US, Inc., Northbrook, Illinois.
Levis MJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Pokaż więcej
Źródło:
Transplantation and cellular therapy [Transplant Cell Ther] 2023 Apr; Vol. 29 (4), pp. 265.e1-265.e10. Date of Electronic Publication: 2022 Dec 13.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
fms-Like Tyrosine Kinase 3*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Adult ; Humans ; Aniline Compounds/therapeutic use ; Aniline Compounds/pharmacology ; Recurrence
Czasopismo naukowe
Tytuł:
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Autorzy:
Zhang W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yu G; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong.
Zhang H; Aptose Biosciences, San Diego, California.
Basyal M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ly C; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yuan B; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ruvolo V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Piya S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bhattacharya S; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhang Q; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Borthakur G; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Battula V; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rice WG; Aptose Biosciences, San Diego, California.
Andreeff M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2023 Jun 01; Vol. 108 (6), pp. 1500-1514. Date of Electronic Publication: 2023 Jun 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
fms-Like Tyrosine Kinase 3*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Humans ; Animals ; Mice ; Agammaglobulinaemia Tyrosine Kinase/genetics ; Apoptosis ; Cell Line, Tumor ; G2 Phase Cell Cycle Checkpoints ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Autophagy ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Attenuation of renal injury by depleting cDC1 and by repurposing Flt3 inhibitor in anti-GBM disease.
Autorzy:
Chen T; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia. Electronic address: .
Cao Q; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.
Wang R; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Nephrology, The Second Hospital of Anhui Medical University, Anhui 230000, China.
Zheng G; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.
Azmi F; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.
Lee VW; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia.
Wang YM; Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW 2145, Australia.
Li H; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; The Department of Gerontology, Anhui Provincial Hospital, the first affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Yu D; Faculty of Medicine, The University of Queensland Diamantina Institute, St Lucia, QLD 4072, Australia.
Rogers NM; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia.
Alexander SI; Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW 2145, Australia.
Harris DCH; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia.
Wang Y; The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.
Pokaż więcej
Źródło:
Clinical immunology (Orlando, Fla.) [Clin Immunol] 2023 May; Vol. 250, pp. 109295. Date of Electronic Publication: 2023 Mar 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-Glomerular Basement Membrane Disease*/drug therapy
CD8-Positive T-Lymphocytes*/metabolism
Drug Repositioning*
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
Animals ; Humans ; Mice ; Dendritic Cells/metabolism ; Kidney/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł:
Emergence of a BCR::ABL1 rearrangement following a uniquely complex clonal evolution pattern in a patient undergoing Fms-like tyrosine kinase 3 inhibitor therapy for acute myeloid leukemia.
Autorzy:
Park B; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Kim J; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Kim M; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Cho YU; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Hwang SH; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Jang S; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Seo EJ; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Choi EJ; Department of Hematology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Park CJ; Department of Laboratory Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło:
International journal of laboratory hematology [Int J Lab Hematol] 2023 Apr; Vol. 45 (2), pp. e24-e27. Date of Electronic Publication: 2022 Sep 30.
Typ publikacji:
Letter; Comment
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Clonal Evolution*/genetics
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Drug Resistance, Neoplasm ; Fusion Proteins, bcr-abl/genetics ; Protein Kinase Inhibitors/therapeutic use
Opinia redakcyjna
Tytuł:
Synergy and antagonism between azacitidine and FLT3 inhibitors.
Autorzy:
Yang J; Department of Chemistry and Biomedical Science, Linnaeus University, Kalmar, SE-39231, Sweden.
Friedman R; Department of Chemistry and Biomedical Science, Linnaeus University, Kalmar, SE-39231, Sweden. Electronic address: .
Pokaż więcej
Źródło:
Computers in biology and medicine [Comput Biol Med] 2024 Feb; Vol. 169, pp. 107889. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Amides*
Aniline Compounds*/pharmacology
Aniline Compounds*/therapeutic use
Azacitidine*/pharmacology
Azacitidine*/therapeutic use
Benzothiazoles*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Phenylurea Compounds*
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Pyrazines*
Pyrimidines*
Humans ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/therapeutic use ; Mutation
Czasopismo naukowe
Tytuł:
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.
Autorzy:
Yu S; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Zhang Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Yu G; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Wang Y; Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Shao R; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Du X; Peking Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Xu N; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Lin D; Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
Zhao W; Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhang X; Department of Hematology, Maoming People's Hospital, Maoming, China.
Xiao J; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Sun Z; Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Deng L; Department of Hematology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liang X; Department of Hematology, The First People's Hospital of Chenzhou, Chenzhou, China.
Zhang H; Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
Guo Z; Department of Hematology, Zhongshan City People's Hospital, Zhongshan, China.
Dai M; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Shi P; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Huang F; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Fan Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Lin R; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Jiang X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Xuan L; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Jin H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
Pokaż więcej
Źródło:
Journal of internal medicine [J Intern Med] 2024 Feb; Vol. 295 (2), pp. 216-228. Date of Electronic Publication: 2023 Oct 29.
Typ publikacji:
Multicenter Study; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Azacitidine*/therapeutic use
Bridged Bicyclo Compounds, Heterocyclic*
Leukemia, Myeloid, Acute*/therapy
Sulfonamides*
Humans ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/therapeutic use ; Homoharringtonine/therapeutic use ; Pathologic Complete Response ; Sorafenib/adverse effects ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged
Czasopismo naukowe
Tytuł:
Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
Autorzy:
Bender O; Biotechnology Institute, Ankara University, Ankara, Turkey.
Shoman ME; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
Ali TFS; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
Dogan R; Biotechnology Institute, Ankara University, Ankara, Turkey.
Celik I; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.
Mollica A; Department of Pharmacy, 'G. d'Annunzio' University of Chieti-Pescara, Chieti, Italy.
Hamed MIA; Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.
Aly OM; Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
Alamri A; Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia.; Molecular Diagnostics Unit and Personalized Treatment, University of Hail, Hail, Saudi Arabia.
Alanazi J; Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia.; Molecular Diagnostics Unit and Personalized Treatment, University of Hail, Hail, Saudi Arabia.
Ahemad N; School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Petaling Jaya, Selangor DE, Malaysia.
Gan SH; School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Petaling Jaya, Selangor DE, Malaysia.
Malik JA; Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
Anwar S; Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia.; Molecular Diagnostics Unit and Personalized Treatment, University of Hail, Hail, Saudi Arabia.
Atalay A; Biotechnology Institute, Ankara University, Ankara, Turkey.
Beshr EAM; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
Pokaż więcej
Źródło:
Archiv der Pharmazie [Arch Pharm (Weinheim)] 2023 Feb; Vol. 356 (2), pp. e2200407. Date of Electronic Publication: 2022 Nov 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
fms-Like Tyrosine Kinase 3*/antagonists & inhibitors
fms-Like Tyrosine Kinase 3*/genetics
fms-Like Tyrosine Kinase 3*/metabolism
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Oxindoles*/pharmacology
Humans ; Apoptosis ; Cell Line, Tumor ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł:
Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
Autorzy:
Kennedy A; Tufts Medical Center, Department of Internal Medicine, Boston, MA, USA.; University of Massachusetts Chan Medical School, Worcester, MA, USA.
Patel S; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Ramanathan M; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Gerber J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Cerny J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 1031-1033. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Letter
MeSH Terms:
Protein Kinase Inhibitors*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Staurosporine/*analogs & derivatives
Humans ; Staurosporine/therapeutic use ; fms-Like Tyrosine Kinase 3/genetics ; Mutation
Opinia redakcyjna
Tytuł:
Distinct karyotypic and mutational landscape in trisomy AML.
Autorzy:
Lam SSY; Division of Haematology, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Tsui SP; Division of Haematology, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Department of Pathology, Queen Mary Hospital, Hong Kong SAR, China.
Fung CY; Division of Haematology, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Saw NY; School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Javed A; School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Ip AHW; Department of Pathology, Queen Mary Hospital, Hong Kong SAR, China.
Ma ESK; Division of Molecular Pathology, Department of Pathology, Hong Kong Sanitorium & Hospital, Hong Kong SAR, China.
Leung AYH; Division of Haematology, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; The Jockey Club Centre for Clinical Innovation and Discovery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong SAR, China.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2024 Mar; Vol. 204 (3), pp. 939-944. Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Journal Article
MeSH Terms:
Nuclear Proteins*/genetics
Leukemia, Myeloid, Acute*/genetics
Humans ; Nucleophosmin ; Trisomy ; Mutation ; Karyotype ; Prognosis ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies